Hamilton Thomas Edward 4

What Happened
Thomas E. Hamilton, a director of Larimar Therapeutics, purchased 100,000 shares of the company's common stock at $5.00 per share on February 27, 2026, for a total of $500,000. The Form 4 reports this as a purchase (transaction code P) in connection with the company's underwritten offering that closed that day — a direct insider buy rather than a sale.

Key Details

• Transaction date: 2026-02-27; Filing date (Form 4): 2026-03-02.
• Shares purchased: 100,000 at $5.00 each; total value $500,000.
• Transaction type/code: Purchase (P) — shares acquired in an underwritten offering (see footnote).
• Footnote: Represents shares purchased in the underwritten offering of Larimar Therapeutics at the offering price, which closed on Feb 27, 2026.
• Shares owned after transaction: Not specified in the provided filing.
• No 10b5-1, gift, exercise, or tax-withholding notes were reported in the supplied details.

Context
This was an insider purchase as part of the company’s underwritten offering — insider buys can be interpreted by investors as a positive sign, though a single purchase does not guarantee future performance. The filing shows a straightforward acquisition of shares rather than an option exercise or sale.